by Molecular cytogenetics is a technique used to identify and analyze chromosomes and genes at the molecular level. It involves combining cytogenetics with molecular biology techniques such as fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR). Molecular cytogenetics has various applications in diagnosing genetic abnormalities during prenatal testing, detecting cancerous cells and for research purposes. With the rising prevalence of cancer worldwide, molecular cytogenetics techniques aid in the diagnosis, prognosis and treatment of various cancers including leukemia, breast cancer and lymphoma. It enables personalized cancer treatment by identifying specific genetic mutations in cancer cells. This provides scope for targeted drug therapies having higher efficacy.
The global Molecular Cytogenetics Market is estimated to be valued at US$ 4211.4 Mn in 2023 and is expected to exhibit a CAGR of 5.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the Global Molecular Cytogenetics Market Size is the ongoing technological advancements. Vendors are focusing on developing novel techniques with higher sensitivity and specificity. For instance, single-cell analysis techniques allow studying genome differences between individual cells, enabling early cancer detection. Array-based comparative genomic hybridization (aCGH) is another advanced technique gaining prominence, as it enables mapping variations in chromosome structures with higher precision. Growing R&D investments by market players as well as funding from government bodies are supporting the development of such advanced molecular cytogenetics techniques. This is expected to augment the market growth over the forecast period.
Porter’s Analysis
Threat of new entrants: Low, as this market requires high initial investments in R&D and machinery. Existing players have established brand names and distribution networks.
Bargaining power of buyers: High, as there are many players offering similar products. Buyers can negotiate on price and demand customized solutions.
Bargaining power of suppliers: Moderate, as suppliers have varying sizes and some raw materials require specific technical expertise. Suppliers often form long-term contracts.
Threat of new substitutes: Low, as molecular cytogenetics techniques have distinct advantages over traditional methods. Significant R&D investment would be required to develop substitutes.
Competitive rivalry: High, as the market comprises many global and regional players competing on product quality, pricing and service. Players focus on expanding their product portfolios and geographic footprints.
Key Takeaways
The global Molecular Cytogenetics Market is expected to witness high growth over the forecast period. The global Molecular Cytogenetics Market is estimated to be valued at US$ 4211.4 Mn in 2023 and is expected to exhibit a CAGR of 5.0% over the forecast period 2023 to 2030.
Regional analysis: North America dominates the market currently due to extensive R&D activities and presence of major players in the region. However, Asia Pacific is expected to grow at the fastest pace during the forecast period with increasing healthcare expenditures and demand for advanced diagnostic techniques in countries like China and India.
Key players: Key players operating in the Molecular Cytogenetics market are UIC, Inc., Shimadzu Corporation, ELTRA GmbH, Xylem Inc., Skalar Analytical B.V.,Hach Company, Inc., GE Analytical Instruments, Inc., Teledyne Analytical Instruments, Mettler-Toledo International Inc., and Analytik Jena AG. UIC leads the market with the widest portfolio of instruments and kits for molecular cytogenetics analysis.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
